Cardiovascular Risk Profile and Prevalence of Microalbuminuria in Patients With Type 2 Diabetes Mellitus: The Campaign Disease Registry Results by M. A, Ebrahim
Journal of Rawalpindi Medical College (JRMC); 2017;21(1): 2-8 
 2 
Original Article 
 
Cardiovascular Risk Profile and Prevalence of 
Microalbuminuria in Patients With Type 2 Diabetes 
Mellitus: The Campaign Disease Registry Results 
 
Ebrahim M. A1, Khan A 2, Zahir M 2, Hassan Z 2 
1. Zubaida  Medical Centre , Karachi ;2.Sanofi-Aventis Pakistan 
 
Abstract 
Background: To assess the cardiovascular risk 
profile of patients with type 2 diabetes mellitus 
(T2DM), the prevalence of microalbuminuria, and 
the prescription pattern in management of overall 
cardiovascular/renal risk in out patient practice.  
Methods: In this cross sectional study consecutive 
adult patients with T2DM signed the informed 
consent and were interviewed by the investigator to 
establish the cardiovascular risk profile. Presence of 
microalbuminuria (20–200mg/l) was diagnosed using 
Micral-Test® strips. Analysis was done by 
descriptive statistics, and multivariate logistic 
regression was performed to identify the 
independent risk-factors for the development of 
microalbuminuria. 
Results: Of the 1763 patients enrolled, data was 
analyzed on 1596 patients. Major cardiovascular risk-
factors included hypertension (55.4%), sedentary 
lifestyle (49.8%), and metabolic syndrome (30.5%). 
Microalbuminuria was prevalent in 55.6% (95% CI 
53.1-58.0) patients. On multivariate analysis, 
significant association was observed with total 
cholesterol (p = 0.029, OR: 2.26, 95% CI: 1.09 – 4.71) 
and diastolic BP (p = 0.015, OR: 2.67, 95% CI: 1.21 – 
5.91). The most commonly prescribed 
antihypertensive drugs were angiotensin-converting 
enzyme inhibitors (41.7%), calcium channel blockers 
(13.2%) and beta blockers (10%), while most 
commonly prescribed antidiabetic drugs were 
sulfonylureas (61.9%), biguanides (56.1%) and 
thiazolidinediones (17.4%). 
Conclusions: Patients with T2DM are at increased 
cardiovascular risk specifically with uncontrolled 
diastolic blood pressure and high total cholesterol 
levels. There is also a high prevalence of 
microalbuminuria in patient with T2DM. 
Key Words: Type 2 diabetes mellitus, 
Cardiovascular risk, Microalbuminuria. 
Introduction 
Diabetes mellitus (DM) is the  commonest  endocrine 
disorder .1,2 Patients with type 2 diabetes mellitus 
(T2DM) often experience a long asymptomatic period 
of hyperglycemia leading to numerous complications 
at the time of diagnosis.3 Diabetic nephropathy (DN), a 
common consequence of long-standing T2DM, has 
become the most common cause of end-stage renal 
disease.4,5 About one third of patients with T2DM 
develop progressive deterioration of renal 
function.6,7Microalbuminuria (MAU) is defined as “a 
urinary albumin excretion rate of 30 to 300 mg in 24 
hour urine collection or of 20 to 200 mg/min in a 
timed overnight urine collection” and is most often the 
primary manifestation of nephropathy in patients with 
DM.8-13  MAU significantly impacts the risk of related 
vascular events like cardiac abnormalities, 
cerebrovascular disease, and, possibly, peripheral 
arterial disease (PAD). 14-18,20,21  The implicit 
associations between the troika of MAU, CV disease 
and progressive renal impairment are being 
unraveled.The hypothesis that “the kidney is a 
window of the vasculature” suggests that albumin 
leakage into the urine is a manifestation of widespread 
vascular damage, it is unclear whether MAU is a cause 
or a consequence of vascular disease. In light of these 
observations, endothelial function and chronic 
inflammation have been advanced as factors 
underlying the association.22, 23 
The risk factors associated with MAU are poor 
glycemic control, insulin resistance , uncontrolled 
hypertension, smoking and central obesity.13,24   In 
patients with T2DM, the risk of MAU is impacted by 
factors including age, gender, body mass index (BMI), 
duration of diabetes, and dyslipidemia [24]. Apart 
from old age and weight gain, hypertension and 
diabetes are reported as the two important 
physiological risk factors for MAU.25 Arterial 
hypertension is known to significantly increase the risk 
of cardio-renal disease when present along with 
T2DM.26 Conversely, a higher rate of prevalence of 
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hypertension is seen in patients with T2DM and 
elevated urinary albumin excretion.27 CV damage like 
left ventricular hypertrophy, carotid artery thickening, 
and other end-organ damage are common 
presentations in hypertensive patients with MAU.28-30  
In addition to the periodic measurement of 
albuminuria in all patients with T2DM and 
hypertension, preventive steps against albuminuria to 
prevent future renal and CV adverse events are 
warranted.9,31,32 Treatment targeting urinary albumin 
levels demonstrably reduce the risk for CV events as 
well as kidney disease progression.31,14  MAU can be 
reversed and the future development of overt DN, and 
consequently, CV risk can be significantly reduced.15,33-
36  
There is a lack of standardized nationwide data from 
Pakistan to define the prevalence of MAU and 
understand its association with adverse CV risk factors 
in patients with T2DM. In view of this, the 
CArdiovascular Risk Profile and Microalbuminuria 
Prevalence in Type 2 DiAbetes Mellitus Patients In the 
Out Patient SettinG In PakistaN (CAMPAIGN) study 
was conducted.  
Patients and Methods 
Present study was a national, multicenter, 
observational, cross-sectional, and epidemiological 
study conducted between April 2009 and July 2009. 
This study aimed to recruit 1800 patients from 100 
centers across 13 cities of Pakistan. The study was 
conducted in the ambulatory care setting, at individual 
outpatient clinics. Exclusion criteria included presence 
of type 1 diabetes, no diabetes, presence of primary 
renal pathology, concomitant urinary tract infection 
(diagnosed either on patient’s history or available 
investigations or both), menstruation, pregnancy and 
refusal of consent. Of the 100 investigators who 
participated in the study, 70 were Physicians and 30 
were specialists such as medical internists, 
diabetologists, and cardiologists.  
This study entailed a single visit. The patients were 
recruited within a period of one month from the date 
of ‘First Patient In’ in the given center. Patients had to 
undergo a Micral-Test® (by Roche Diagnostics) on the 
day of the consultation at the investigator’s clinic. The 
test was performed using test strips for the 
immunological, semi-quantitative in vitro 
determination of urinary albumin from morning urine 
sample. A value of 20-200 mg/l of albumin was 
judged as pathological. Our objective was to identify 
the proportion of T2DM suffering from 
Microalbuminuria (Micral test strips) in outpatient 
practice and not Clinical (Macroalbuminuria (> 200 
mg/l)). Patients with > 200 mg/l were not specifically 
identified on 24 hours urinary/albumin test as the 
patient was diagnosed on Micral test.  
Information on lipid profile including total cholesterol, 
high density lipoprotein (HDL), low density 
lipoprotein, very low density lipoprotein, triglycerides 
and other investigations such as serum creatinine, 
fasting blood glucose, random blood glucose, and 
abnormal glucose metabolism (HbA1c) was recorded  
Pakistan has a diabetic population of 5.2 million.37 In 
the DAP-WHO study , non-insulin dependent diabetes 
was reported as 98.0%. 38 This makes the population 
with non-insulin dependent diabetes mellitus 
equivalent to 5,096,000 patients with T2DM. As there 
were  no local statistics available on CV risk profile 
(primary objective of this study), the best estimate was 
assumed to be 50.0%. Estimates show the prevalence 
of MAU as 34.0% in a study conducted in Karachi, 
Pakistan [39]. In order to capture the lower estimated 
prevalence between MAU and CV risk profile, 34% 
was plugged in as the expected frequency of MAU in 
the universal population of patients with T2DM with 
an assumption of a worst acceptable prevalence of 
37%. Aiming for 99% confidence level and 3% 
precision, a sample size of 1,654 was required. 
Accounting for incomplete forms, ineligible patients 
etc., a sample size of 1800 patients was proposed. 
Estimations were done at country level.  
Analysis population included only those who met 
inclusion and exclusion criteria and on whom all 
responses were documented and Micral-Test® was 
performed. CV risk variables were assessed as 
categorical and continuous variables depending on 
variable type. Continuous variables were reported as 
means with standard deviations. No comparisons 
were envisaged as this was a descriptive exploratory 
study. Bivariate analysis was performed to identify the 
associations between MAU and CV risk factors. 
Factors that showed a significant association with 
MAU in bivariate analysis were entered into a logistic 
regression to identify the independent risk factors for 
the development of MAU. In both the analyses, a p 
value <0.05 was considered significant. 
Results 
Of 1763 patients enrolled , 1596 (90.5%) patients were 
evaluable in this study. Remaining patients (167) were 
excluded because they did not meet the inclusion 
criteria. The mean age of the patients was 52.7 (±10.4) 
years and 83.5% of patients were between 4th to 6th 
decades of life. An equal gender distribution was 
observed among patients (49.9% men vs. 51.1% 
women). The mean duration of T2DM was 6.8 (±5.5) 
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years with a mean age at diagnosis of 43.8 (±12.6) 
years. About 65% of the patients had a BMI ≥25 
kg/m2. Mean waist circumference was 99.4 (±13.2) cm. 
Mean height and mean weight was 161.6 (±10.9) cm 
and 73.7 (±13.6) kg respectively. Uncontrolled 
hypertension was observed in 58.0% of patients at the 
time of visit(Table 1). Patients with a known case of 
hypertension were 55.4% (884/1596 ) in which 19.1% 
(169/884) had a controlled BP. Patients with a history 
of antihypertensive intake was 50.3% (802/ 1596) in 
which 20.7% (166/802) had a controlled BP.  
Micral-Test was performed on a random urine sample 
in 81% patients and on an early morning sample in 
17% patients. More than half of the patients (55.6%; 
95% CI: 54.2% - 59.1%) with T2DM in outpatient 
practice were detected to have urinary albumin 
excretion of 20-200 mg/L on the test. Only 10.7% had a 
similar test done prior to this study.  
The major CV risk factors based on patients’ history 
included hypertension in 55.4% patients, sedentary 
lifestyle in 49.8% patients and metabolic syndrome in 
30.5% patients.  Bivariate analysis was performed to 
study the correlation between CV risk factors and 
MAU . Compared to proportion of patients with 
negative Micral-Test results the analysis indicated a 
significant association between positive MAU and 
systolic BP ≥130 mm Hg (p <0.01), diastolic BP ≥85 
mm Hg (p <0.01), fasting blood glucose >140 mg/dL 
(p = 0.008), total cholesterol ≥200 mg/dL (p = 0.003), 
triglycerides >200 mg/dL (p = 0.02), HbA1c >7 (p = 
0.004), sedentary lifestyle (p = 0.02), family history of 
premature CV disease in first degree relative before 50 
years of age (p = 0.002), hypertension (p <0.01), 
diabetic nephropathy (p <0.01), congestive heart 
failure (p <0.01), metabolic syndrome (p <0.01), CAD 
(p <0.01), PAD (p <0.01) and mean duration of 
diabetes (p <0.01). Out of 1596 patients enrolled in the 
study, HbA1c was available for 553 patients. Of the 
553 patients, 412 patients had HbA1c > 7%. i.e 26% of 
all patients had an elevated HbA1c. Of the 412 
patients, 253 (61.4%) MAU positive patients had an 
HbA1c >7 (Table 2). Significant association was 
observed with total cholesterol (p = 0.029, OR: 2.26, 
95% CI: 1.09 – 4.71) and diastolic BP (p = 0.015, OR: 
2.67, 95% CI: 1.21 – 5.91). Patients with MAU were 2.26 
times more likely to have high total cholesterol levels 
and 2.67 times more likely to have high diastolic BP. 
High cholesterol and DBP does contribute to the 
model with higher average for the MAU positive after 
controlling other factors constant. 
Table 1.Demographic and clinical characteristics 
of patients (n = 1596) 
Parameters Values* 
Mean age (years) 52.7 ± 10.4 
Mean Age at diagnosis (years) 43.8 ± 12.6 
Mean Duration of diabetes (years) 6.8 ± 5.5 
Mean Weight (kg) 73.7 ± 13.6 
Mean Height (cm) 161.6 ± 10.9 
Proportion of Males  49.9 
Mean BMI 28.3 ± 5.6 
Proportion overweight (25 – 29.9 kg/m2) 36.0 
Proportion Obese (≥ 30.0 kg/m2) 29.0 
Mean Waist circumference (cm) 99.4 ± 13.2 
Proportion (%) of  males with WC  ≥ 90 
cm 
34.9 
Female  ≥ 80 cm 39.6 
Mean systolic blood pressure (mm Hg) 135.6 ± 19.8 
Mean diastolic blood pressure(mm Hg) 85.9 ± 11.1 
SBP ≥ 130 mm Hg / DBP ≥ 80(mm Hg) 925 (58.0) 
HbA1c (%) 8.5 ± 4.3 
*All values are mean ± SD except values expressed for 
gender, overweight, obesity, waist circumference for male 
and female, and SBP ≥ 130 / DBP ≥ 80, which are in n (%) 
;BMI, body mass index; WC, waist circumference; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; 
HbA1c, glycosylated haemoglobin.  
 
The most common antihypertensive drug classes 
prescribed to the patients with T2DM were 
angiotensin-converting enzyme (ACE) inhibitors 
(41.7%).Similarly, the most common oral antidiabetic 
drug pioglitazone (16.6%) being the most prescribed 
drugs in each category, respectively (Table 3).
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Table 2. Bivariate analysis of risk factors and microalbuminuria (n = 1596) 
Risk Factors 
+MAU, 
 n (%) 
-MAU,  
n (%) 
p-value 
BP systolic mmHg 
<130 214 (41.1) 307 (58.9) 
<0.01 
≥ 130 632 (64.6) 346 (35.4) 
BP diastolic mmHg 
< 85 335 (47.1) 376 (52.9) 
<0.01 
≥ 85 511 (64.8) 277 (35.2) 
FBG mg/dL 
≤ 140 260 (53.8) 223 (46.2) 
.008 
>140 243 (62.8) 144 (37.2) 
Total Cholesterol mg/dL 
< 200 178 (51.1) 170 (48.9) 
.003 
≥ 200 137 (64.0) 77 (36.0) 
Triglycerides mg/dL 
< 200 134 (51.1) 128 (48.9) 
0.02 
≥ 200 106 (62.7) 63 (37.3) 
HbA1c (%) 
≤ 7 67 (47.5) 74 (52.5) 
0.004 
>7 253 (61.4) 159 (38.6) 
Gender 
Male 437 (54.8) 360 (45.2) 
0.14 
Female 462 (58.5) 328 (41.5) 
Sedentary lifestyle 
Yes 479 (60.3) 316 (39.7) 
0.02 No 316 (53.1) 279 (46.9) 
Unknown 53 (54.1) 45 (45.9) 
Family history of premature CVD in 1st degree relative < 50 
years of age 
Yes 233 (62.3) 141 (37.7) 
0.002 No 462 (53.5) 402 (46.5) 
Unknown 125 (64.1) 70 (35.9) 
Hypertension 
Yes 578 (65.4) 306 (34.6) 
<0.01 No 259 (43.7) 334 (56.3) 
Unknown 24 (68.6) 11 (31.4) 
Diabetic Nephropathy 
Yes 286 (80.8) 68 (19.2) 
<0.01 No 476 (47.1) 534 (52.9) 
Unknown 89 (68.5) 41 (31.5) 
Congestive Heart Failure 
Yes 76 (69.7) 33 (30.3) 
<0.01 No 705 (55.0) 577 (45.0) 
Unknown 65 (67.7) 31 (32.3) 
Metabolic Syndrome 
Yes 304 (62.4) 183 (37.6) 
<0.01 No 477 (53.8) 409 (46.2) 
Unknown 59 (62.8) 35 (37.2) 
Coronary Artery Disease 
Yes 115 (65.7) 60 (34.3) 
<0.01 No 646 (54.4) 541 (45.6) 
Unknown 94 (67.6) 45 (32.4) 
Peripheral Artery Disease 
Yes 102 (69.9) 44 (30.1) 
<0.01 
No 664 (54.4) 557 (45.6) 
Unknown 83 (65.9) 43 (34.1) 
History of Stroke 
Yes 28 (56.0) 22 (44.0) 
0.53 No 786 (56.7) 600 (43.3) 
Unknown 39 (63.9) 22 (36.1) 
History of MI 
Yes 44 (61.1) 28 (38.9) 
0.08 No 760 (56.2) 593(43.8) 
Unknown 47 (69.1) 21 (30.9) 
Duration of diabetes (years) 
<1 yrs 48 (46.2) 56 (39.9) 
<0.01 
1-5 yrs 352 (50.3) 348 (49.7) 
6-8 yrs 165 (63.7) 94 (36.3) 
9-11 yrs 159 (65.7) 83 (34.3) 
>11 157 (61.1) 100 (38.9) 
MAU, microalbuminuria; BP, blood pressure; FBG, fasting 
blood glucose; HbA1c, glycosylated haemoglobin; CVD, 
cardiovascular disease; MI, myocardial infarction 
 
Table 3.Distribution of patients based on 
prescription pattern (n = 1596) 
Prescribed drugs n (%) 
Class of antihypertensive drugs 
ACE inhibitors 666 (41.7) 
Calcium channel blockers 211 (13.2) 
Beta blockers  162 (10.2) 
Angiotensin receptor 
blockers 
145 (9.1) 
Diuretics 120 (7.5) 
Nitrates 26 (1.6) 
Others 113 (7.1) 
Class of antidiabetic drugs 
Sulfonylureas 988 (61.9) 
Biguanides 896 (56.1) 
Thiazolidinediones 278 (17.4) 
Insulin 167 (10.5) 
Alpha glucosidase 
inhibitors 
47 (2.9) 
ACE, angiotensin-converting enzyme 
 
Monotherapy was given to 36.6% and 39.3% of 
patients using antidiabetic and antihypertensive 
drugs, respectively; while remaining proportion of 
patients from both the classes were given treatment 
using combination of 2 drugs in 56.1% and 13.7%, 3 
drugs in 8.6% and 3.6% and 4 drugs in 0.9% and 1.1%, 
respectively. 
Discussion 
In this large prospective epidemiological study a  high 
burden was found , of MAU ,in patients with T2DM in 
outpatient setting in Pakistan. Major CV risk factors 
observed among the patients were hypertension, 
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sedentary lifestyle and metabolic syndrome. More 
than half of the patients (55.6%) with T2DM in 
outpatient practice were detected to have urinary 
albumin excretion of 20-200mg/L on the Micral test.  
A value of 20-200 mg/L of albumin was judged as 
pathological.  The well-established risk factors that 
showed high significance included fasting blood 
glucose, total cholesterol, poor glycemic control, family 
history, hypertension, metabolic syndrome, 
microvascular complications and duration of diabetes. 
The study also offers interesting hypothesis  about the 
possible independent role of diastolic BP and total 
cholesterol levels as independent correlates of MAU. 
The prevalence of MAU in the study population was 
55.6% (95% CI 53.1 – 58.0). It could also reflect a rapid 
rise in cases where kidneys are impacted because of 
uncontrolled and poor glycemic control. 40-42   
The association of MAU with hypertension has long 
been established and is known to be accompanied by 
left ventricular diastolic dysfunction and left 
ventricular hypertrophy.43-45 MAU was found to be 
significantly associated with hypertension in the 
current study, in accordance with previous findings.46 
Similar findings were observed in previous studies 
that reported systolic BP and diastolic BP to be 
associated with MAU.43-48  Multivariate logistic 
regression also reported diastolic BP to be significantly 
associated with MAU in the current study.  
A higher incidence of silent myocardial infarction has 
been reported in T2DM patients with MAU compared 
to normoalbuminuria. 49 While the trends of 
association between specific CV events and MAU vary 
between these studies, they are in agreement about the 
overall relationship between CV risks with MAU. 
High triglyceride levels, a significant CV risk factor, 
could initiate endothelial damage and eventually 
induce renal disease in patients with T2DM. 50 High 
triglyceride levels were significantly associated with 
presence of MAU which confirms data from a study in 
Pakistan where 93.7% patients with MAU had 
triglyceride>150 mg/dL. 11 According to World Health 
Organization and other studies , MAU is one of the 
most important components of metabolic syndrome. 
51,52   
A significant correlation was observed between 
increased HbA1c and MAU in our study population 
corroborating results from other studies [40,53]. 
Euglycaemia exerts a stronger influence on MAU than 
macroalbuminuria, implying that early glycaemic 
control must be considered to avoid the onset of 
nephropathy rather than initiating diabetes 
management post-onset.54   
In the current study effects of  life style on CV risk in 
T2DM patients with MAU was assessed. So far, only 
few studies indicate smoking as a risk factor for 
albuminuria among patients with T2DM.55 A 
statistically non-significant difference was seen in the 
smoking status of patients in MAU positive and 
negative groups, though more patients in the MAU 
positive group were past or current smokers.  
In present study, ACE inhibitors were the most 
commonly prescribed antihypertensive drugs, 
followed by calcium channel blockers, beta blockers, 
angiotensin-receptor blockers (ARBs), and diuretics. 
Recent guidelines advocate the use of ACE inhibitors 
as the first choice for diabetic hypertension and 
ARB+ACE inhibitors for DN.56-58 Addition of beta 
blockers to ACE inhibitors improves endothelial 
function and reduces urinary albumin excretion in 
T2DM patients with MAU.59 In patients with 
congestive heart failure, ARBs are recommended as a 
first-line drug by American Diabetes Association for 
their superiority over calcium channel blockers in 
reducing heart failure.60,61 The prophylactic use of beta 
blockers is recommended for high risk patients, in 
view of its post-myocardial infarction protective effect 
on CV mortality. ACE inhibitor or ARBs result in 
significant CV and/or renal morbidity reductions in 
patients with albuminuria, with or without good 
glycaemic control.62 The prescription pattern of 
antihypertensive drugs in the present study was found 
to be consistent with the evidence-based guidelines.  
In this study, sulphonylureas were most commonly 
prescribed antidiabetic drugs followed by biguanides 
and thiazolidinediones. A similar pattern of 
prescription was observed in studies from Asia.63,64 
The prescription pattern of different classes of drugs in 
patients with T2DM in Pakistan was found to be 
rational and, to a great extent, compliant with 
evidence-based guidelines. 
Conclusion 
1. Prevalence of MAU in Pakistani patients with T2DM 
is high. These patients are also at an increased CV risk, 
specifically with uncontrolled diastolic BP and high 
total cholesterol levels.  
2. Early screening strategies for DN, with better 
glycemic, hypertension and cholesterol control will aid 
in averting/reducing adverse cardiovascular 
consequences in these patients. 
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